fashion -WSS

fashion

author：knowledge 2025-09-06 02:12:54 - browse：1967

STAT's Megan Molteni speaks with Feng Zhang in New York on March 21, 2024 — Scientist Feng Zhang, right, is interviewed by reporter Megan Molteni at STAT's Breakthrough Summit East. STAT

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders.

But now, a decade later, Editas is seen as lagging behind its peers. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, won the race to get the first CRISPR-based medicine across the finish line. Intellia Therapeutics was the first to show that CRISPR editing could be performed inside the body. Editas, meanwhile, has seen a revolving door among its executives.

So what happened?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： An Ebola outbreak presents a new mystery involving children

explore

WSS

FDA approves updated Covid vaccines

‘The Bear’ and hospitality in hospitals

WATCH: Why do bright lights make us see spots?

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

FDA approves updated Covid vaccines

leisure time

fashion

hotspot

Jerome Adams on the need for new antivirals for Covid

Will the IRA bring competition to the biologics market?

Apple is now the first public company to be valued at $3 trillion

Popular nasal decongestant doesn't actually relieve congestion

Medicare proposal to cover medical devices draws a mixed reaction

Astronauts get first look at the spacecraft that will fly them around the moon

Wildfire smoke exposes gaps in outdoor worker protections

Acelyrin, a rare IPO success, stumbles in its first big test

Trump demands the U.S. pay no more for drugs than other countries … again

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

Long Covid needs a new name — and a new frame

Wegovy cuts risk of cardiovascular events by 20%, study finds

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

How medical schools plan to diversify without affirmative action

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

What to make of Biden’s latest efforts on cancer research

entertainment

explore

knowledge

entertainment